改变糖尿病治疗模式：DPP-4 抑制剂在心血管和肾脏保护方面作用的拓展。
Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection.
机构信息
Medicine Department, Institut d'Investigació i Innovació Parc Taulí I3PT, Parc Taulí Hospital Universitari, 08208 Sabadell, Spain.
出版信息
Medicina (Kaunas). 2024 Nov 1;60(11):1793. doi: 10.3390/medicina60111793.
Abstract
The approach to managing type 2 diabetes mellitus (T2DM) has significantly progressed, evolving beyond strict glycemic control to addressing the wider complications associated with the disease, including cardiovascular disease (CVD) and chronic kidney disease (CKD) [...].
摘要
管理 2 型糖尿病（T2DM）的方法已经取得了显著进展，已经超越了严格的血糖控制，转而解决与该疾病相关的更广泛的并发症，包括心血管疾病（CVD）和慢性肾脏病（CKD）[...]。
相似文献
1
Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection.改变糖尿病治疗模式：DPP-4 抑制剂在心血管和肾脏保护方面作用的拓展。
Medicina (Kaunas). 2024 Nov 1;60(11):1793. doi: 10.3390/medicina60111793.
2
Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.二肽基肽酶-4抑制在慢性肾脏病中的作用及预防糖尿病相关肾损伤的潜力
Nutr Metab Cardiovasc Dis. 2016 May;26(5):361-73. doi: 10.1016/j.numecd.2016.01.001. Epub 2016 Jan 13.
3
Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.患有糖尿病且伴有或不伴有慢性肾病的患者使用二肽基肽酶-4 抑制剂与心血管事件风险相关：一项全国性队列研究。
PLoS One. 2019 May 21;14(5):e0215248. doi: 10.1371/journal.pone.0215248. eCollection 2019.
4
DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.临床实践中糖尿病合并慢性肾脏病及终末期肾病透析患者使用二肽基肽酶-4抑制剂的情况
Contrib Nephrol. 2015;185:98-115. doi: 10.1159/000380974. Epub 2015 May 19.
5
Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.2 型糖尿病患者在肾功能损害各阶段的血糖控制：初级保健提供者的信息。
Postgrad Med. 2018 May;130(4):381-393. doi: 10.1080/00325481.2018.1457397. Epub 2018 Apr 18.
6
Management of type 2 diabetes mellitus in chronic kidney disease.慢性肾脏病患者2型糖尿病的管理
Curr Med Res Opin. 2015 Jan;31(1):95-7. doi: 10.1185/03007995.2014.977993. Epub 2014 Oct 28.
7
[Newer anti - diabetic therapies and chronic kidney disease].[新型抗糖尿病疗法与慢性肾脏病]
G Ital Nefrol. 2017 Jan-Feb;34(1).
8
Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.二肽基肽酶-4 抑制剂在 2 型糖尿病合并慢性肾脏病患者中的应用。
Postgrad Med. 2012 Jul;124(4):138-44. doi: 10.3810/pgm.2012.07.2575.
9
Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy.胰高血糖素样肽-1受体激动剂与二肽基肽酶4抑制剂在晚期慢性肾脏病和终末期肾病中的应用：真实世界的治疗效果和治疗持续性
J Diabetes Complications. 2025 Jan;39(1):108925. doi: 10.1016/j.jdiacomp.2024.108925. Epub 2024 Dec 4.
10
[New oral hypoglycemic drugs in diabetic kidney disease].[糖尿病肾病中的新型口服降糖药物]
Wiad Lek. 2017;70(6 pt 2):1193-1196.
引用本文的文献
1
Heterogeneity in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Phenotypic Classifications and Clinical Implications.射血分数保留的心力衰竭的异质性：表型分类和临床意义的系统评价
J Clin Med. 2025 Jul 8;14(14):4820. doi: 10.3390/jcm14144820.
2
Comparative effectiveness of combining antidiabetic medications to treat renal impairment in patients with type 2 diabetes mellitus.联合使用抗糖尿病药物治疗2型糖尿病患者肾功能损害的比较有效性
Sci Rep. 2025 Jul 16;15(1):25735. doi: 10.1038/s41598-025-10299-1.
3
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review.二肽基肽酶-4抑制剂对糖尿病合并心力衰竭患者的影响：深入综述
Medicina (Kaunas). 2024 Dec 2;60(12):1986. doi: 10.3390/medicina60121986.
Zotero 插件